It has been reported that several factors are associated with response to dual ICIs and VEGF inhibitor treatment, including angiogenesis, PD‐L1 expression, T‐cell response and myeloid inflammation signature in renal cancer and hepatocellular carcinoma.26, 27. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.